XENETIC BIOSCIENCES, INC. — Earnings
Most recent reported period: FY2025 (Q4) (filed for period ending 2025-12-31) · sourced from SEC EDGAR
Recent earnings · last 8 quarters
| Quarter end | Revenue | YoY | Net Income | YoY | Op. Margin |
|---|---|---|---|---|---|
| 2025-12-31 | $766K | ↑+18.1% | — | — | — |
| 2025-09-30 | $1M | ↑+67.2% | $-510K | ↓-16.8% | -53.0% |
| 2025-06-30 | $590K | ↓-18.8% | $-689K | ↑+45.9% | -122.8% |
| 2025-03-31 | $593K | ↑+16.1% | $-903K | ↑+24.4% | -158.9% |
| 2024-12-31 | $649K | ↓-3.4% | — | — | — |
| 2024-09-30 | $614K | ↑+0.5% | $-437K | ↑+58.6% | -81.3% |
| 2024-06-30 | $726K | ↑+11.6% | $-1M | ↓-21.2% | -184.1% |
| 2024-03-31 | $511K | ↓-15.7% | $-1M | ↓-39.5% | -248.3% |
Analyst consensus estimates (EPS / Revenue) and implied move from options will land in a follow-up wave. For now, YoY-vs-prior-year-quarter is the surprise proxy.
Last earnings · FY2025 (Q4)
Earnings surprise · last 8 quarters
YoY % change · proxy for analyst surprise until estimates landEPS history · last 10 fiscal years
diluted, GAAP, annualNote: EPS reflects WEIGHTED-AVERAGE diluted shares for each fiscal year. Pre-stock- split values can blow up the early bars if SEC's XBRL data isn't split-adjusted — flagged as a known limitation; cumulative split-adjustment is a follow-up.
Margin trends · 61 quarters
margin trajectory tells the operating-leverage storyGo deeper
XBIO Sankey — flow of dollars
See how revenue waterfalls through every line item to net income for the latest reported quarter, with prior-period comparison.
Open SankeyXBIO Key Metrics — EPS, ROE, ROIC
10 CFA-grade fundamental ratios — EPS, BVPS, ROE, ROA, ROIC, Debt/Equity, Current Ratio. Compare across years.
Open Key Metrics